Gilteritinib / Xospata (Everest)

💊 Product Overview

Gilteritinib (Brand name: Xospata) is an oral FMS-like tyrosine kinase 3 (FLT3) inhibitor primarily used for the treatment of adult patients with acute myeloid leukemia (AML) carrying FLT3 mutations.

By selectively inhibiting signaling pathways activated by FLT3-ITD and FLT3-TKD mutations, Gilteritinib helps suppress leukemia cell proliferation and survival. Gilternib, manufactured by Everest Pharma, is a high-quality generic version formulated with the same active ingredient and comparable therapeutic performance, providing a more accessible treatment option for patients worldwide.

🎯 Mechanism of Action & Advantages

✅ Targets both FLT3-ITD and FLT3-TKD mutations
✅ Also inhibits AXL receptor tyrosine kinase, helping reduce treatment resistance
✅ Can be used as monotherapy or as part of combination treatment strategies
✅ Multiple clinical studies have demonstrated improvements in response rates and overall survival

Gilteritinib has been approved by the U.S. FDA and Japan PMDA and is included in NCCN guideline recommendations as a standard treatment option for relapsed or refractory FLT3-mutated AML.

📌 Indications

Gilteritinib is indicated for:

• Adult patients with relapsed or refractory acute myeloid leukemia (AML) carrying FLT3 mutations (ITD or TKD) confirmed through validated molecular testing

FLT3 mutation status should be confirmed using certified laboratory testing methods prior to treatment initiation.

💡 Dosage and Administration

👥 1. Patient Selection

• All patients should undergo FLT3 mutation testing before starting treatment
• Therapy should be initiated under the supervision of a physician experienced in oncology treatment

💊 2. Administration Instructions

• Oral tablet formulation
• May be taken with or without food
• Swallow tablets whole; do not split, crush, or chew
• Take at the same time each day to maintain stable drug levels

Missed Dose Guidance

• If a dose is missed, take it as soon as possible, ensuring at least 12 hours before the next scheduled dose
• If vomiting occurs after administration, do not take an additional dose; continue with the next scheduled dose
• Patients at risk of relapse following hematopoietic stem cell transplantation (HSCT) may continue or restart Gilteritinib treatment when appropriate

📈 Recommended Dosage

💡 Continued treatment is generally recommended until disease progression, lack of clinical benefit, or unacceptable toxicity occurs. If early remission is not achieved, treatment for up to 6 cycles may be considered before evaluating effectiveness.

🩺 Monitoring Recommendations During Treatment

Blood Tests & Biochemical Monitoring

• Before treatment initiation
• Weekly during the first treatment cycle
• Every two weeks during the second cycle
• Prior to each subsequent cycle

ECG Monitoring

• Day 8 and Day 15 of the first cycle
• Before each following cycle

If QTcF interval exceeds 500 ms, treatment interruption and clinical reassessment are recommended.

⚠️ Important Precautions

• Use caution when combined with medications known to prolong the QT interval
• Regular monitoring of creatine kinase, liver enzymes, and renal function is recommended
• Contraindicated during pregnancy and breastfeeding; effective contraception is advised throughout treatment

📦 Packaging & Storage

• Strength: 40 mg tablets
• Packaging: 90 tablets per bottle (approximately 30 days at 120 mg daily dosing)
• Storage: Store at room temperature away from moisture and direct light

📚 Additional Resources

For more information regarding clinical efficacy, adverse reactions, pharmacokinetics, or combination therapy research involving Gilteritinib, refer to:

• NCCN Guidelines for Acute Myeloid Leukemia
• ClinicalTrials.gov — ongoing AML clinical studies and research updates